Last reviewed · How we verify
Malignant tumor of penis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Blenoxane | BLEOMYCIN | Bristol-Myers Squibb | Cytoprotective Agent | Aspartyl/asparaginyl beta-hydroxylase | 1973-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Bristol-Myers Squibb · 1 drug in Malignant tumor of penis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Malignant tumor of penis:
- Malignant tumor of penis treatment updates — RSS
- Malignant tumor of penis treatment updates — Atom
- Malignant tumor of penis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Malignant tumor of penis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/malignant-tumor-of-penis. Accessed 2026-06-10.
Related
- Malignant tumor of penis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing